Moreover, aberrant activation of both PI3K/Akt/mTOR and MAPK/ERK signalling pathways has been associated with resistance to conventional therapy in breast cancer, including both chemotherapy and endocrine therapy [33-35]. Here, PIK3CA is linked to breast carcinoma.